CD274 and urinary bladder carcinoma: Interestingly, treatment with PARP-inhibitors as a single agent therapy (NCT03375307), or in association with the anti PD-L1 drug durvalumab (NCT02546661), an antitumor immune checkpoint drug, are in Phase II/Phase1b clinical trials, respectively, for bladder cancer [28, 41, 42].